Aurobindo Pharma anticipates initiating production at its new facility in China during the upcoming quarter, with full-scale operations expected to start in the next fiscal year. Chief Financial Officer Santhanam Subramanian outlined the timeline, indicating a small-volume rollout from November to December, with a ramp-up projected for the January-March period of the following year.
The Hyderabad-based pharmaceutical company aims to commercialize the plant by Q3 FY25, with increased production expected from Q4 FY25. Full production is slated to begin in FY26. “We are also pursuing filings for both China and the US markets, which should enhance the revenue potential from China in the coming years. For this fiscal year, we anticipate only limited volume and value,” Subramanian mentioned during an analyst call.
Additionally, Aurobindo Pharma is progressing with the large-scale commercial rollout of its Pen-G (penicillin) plant in Andhra Pradesh. The ₹2,400 crore facility, which is supported by the Production-Linked Incentive (PLI) Scheme, is set to have an annual production capacity of approximately 15,000 tonnes. The company plans to significantly increase production from October this year.
Regarding its US operations, Subramanian expects the current pricing environment to remain stable. The company also foresees continued growth in Europe and other emerging markets. Aurobindo Pharma is confident of meeting its internal EBITDA margin target of 21-22% for the fiscal year. For the April-June quarter, the company reported a 61% increase in consolidated net profit, reaching ₹919 crore, with revenue from operations at ₹7,567 crore.
Aurobindo Pharma is a major Indian pharmaceutical company renowned for its extensive range of generic and specialty medications. Established in 1986, the company has grown into a global player in the pharmaceutical industry, with a robust portfolio that includes antibiotics, antiretrovirals, and cardiovascular drugs, among others.
Aurobindo Pharma operates multiple manufacturing facilities across India and the United States, adhering to rigorous international quality standards. Its strategic focus on research and development, along with its strong presence in both developed and emerging markets, has positioned the company as a key supplier in the global healthcare sector.
Aurobindo Pharma is also committed to expanding its therapeutic offerings and increasing its footprint in biosimilars and complex generics, driving innovation and improving access to affordable medications worldwide.
